摘要
目的 研究不同剂量阿托伐他汀改善老年急性脑梗死(ACI)患者认知功能及调控Akt1/caspase-3通路的差异。方法 选择2018年1月至2020年12月期间河北省第八人民医院收治的83例老年ACI患者作为研究对象,根据阿托伐他汀降脂剂量不同分为每日40 mg强化降脂的观察组、每日20 mg常规降脂对照组,治疗前及治疗后21 d时检测血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDLC)、高密度总蛋白胆固醇(HDLC)、caspase-3含量,外周血Akt1表达水平,采用美国国立卫生研究院脑卒中量表(NIHSS)评价神经功能,采用改良Rankin量表(mRS)评价预后,采用简易精神状态量表(MMSE)、蒙特利尔认知评估量表(MoCA)评价认知功能,观察不良反应发生率。结果 治疗后,两组的HDLC比较差异无统计学意义(t=0.453,P>0.05)。观察组的TC、LDLC、NIHSS评分、预后不良发生率、血清caspase-1含量低于对照组,MMSE评分、MoCA评分及外周血Akt1表达水平高于对照组,差异有统计学意义(t/χ^(2)=3.773、3.193、9.598、6.592、4.572、3.823、8.384、7.521,P<0.05);两组不良反应发生率的比较,差异无统计学意义(χ^(2)=0.051,P>0.05)。结论 每日40 mg阿托伐他汀强化降脂改善老年ACI患者的认知功能并调控Akt1/caspase-3通路。
Objective To investigate the differences in the improvement of cognitive function and regulation of Akt1/caspase-3 pathway in elderly patients with acute cerebral infarction(ACI)by different dos-es of atorvastatin.Methods 83 elderly patients with ACI admitted to Hebei Eighth Peoples Hospital from January 2018 to December 2020 were selected as the study subjects.They were divided into the observation group received 40 mg of intensive lipid lowering daily and the control group received 20 mg of conventional lipid lowering daily according to the different lipid lowering doses of atorvastatin.Before and 21 days after treatment,the levels of serum total cholesterol(TC),low density lipoprotein cholesterol(LDLC),high den-sity total protein cholesterol(HDLC)and caspase-3 were measured,the expression level of Akt1 in peripheral blood was measured,the neurological function was evaluated by National Institutes of Health Stroke Scale(NI-HSS),the prognosis was evaluated by modified Rankin scale(mRS),and the cognitive function was evaluat-ed by the Mini-Mental State Scale(MMSE)and Montreal Cognitive Assessment Scale(MoCA).The inci-dence of adverse reactions was observed.Results After treatment,there was no significant difference in HDLC between the two groups(t=0.453,P>0.05).The TC,LDLC,NIHSS score,incidence of poor progno-sis and serum caspase-1 content in the observation group were lower than those in the control group,while the MMSE score,MoCA score,and Akt1 expression level in peripheral blood were higher than those in the con-trol group(t/X^(2)=3.773,3.193,9.598,6.592,4.572,3.823,8.384,7.521,P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups of patients(X^(2)=0.051,P>0.05).Conclusion 40 mg of atorvastatin daily enhances lipid-lowering and improves cognitive function in el-derly ACI patients,regulating the Akt1/caspase-3 pathway.
作者
罗力亚
耿丽洁
刘姗姗
张伟
张帅
刘翠青
LUO Liya;GENG Lijie;LIU Shanshan;ZHANG Wei;ZHANG Shuai;LIU Cuiqing(Department of Geriatric,the Eighth Peoples Hospital of Hebei,Shijiazhuang,Hebei,China,050000;Functional Department of the Eighth Peoples Hospital of Hebei,Shijiazhuang,Hebei,China,050000;De-partment of Laboratory medicine,the Eighth Peoples Hospital of Hebei,Shijiazhuang,Hebei,China,050000)
出处
《分子诊断与治疗杂志》
2023年第11期1903-1906,1912,共5页
Journal of Molecular Diagnostics and Therapy
基金
河北省卫生和计划生育委员会科研基金项目(20180685)。
